Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Share News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,898.00
Bid: 1,898.00
Ask: 1,902.00
Change: 6.00 (0.32%)
Spread: 4.00 (0.211%)
Open: 1,852.00
High: 1,908.00
Low: 1,852.00
Prev. Close: 1,892.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Genus holds gloomy guidance as tough conditions persist

Thu, 22nd Feb 2024 08:42

(Sharecast News) - There were few surprises in Genus's interim results on Thursday after a detailed trading update from the animal genetics company just last week, as it reported a 31% drop in adjusted profits as expected.

Shares in Genus tanked 16% on 15 February after the company guided to full-year adjusted pre-tax profit of £58m, owing to challenging markets, well below the consensus forecast for a similar outcome from last year's £71.5m.

However, an absence of bad news its interim results has provided some reassurance, with shares rising 2.5% at 1,960p following the figures on Thursday morning.

In line with recent guidance, Genus said revenues were £334m in the six months to 31 December, down 5% on the previous year, which it described as "resilient" in a tough environment. At constant currency, revenues would have risen 1%.

Adjusted pre-tax profit was down 26% year-on-year on a reported basis at £29m due to weakness in China, particularly in its porcine business PIC and dairy/cattle unit ABS. In the latter specifically, demand for dairy genetics in China was hit by a double-digit decline in the dairy herd.

As mentioned last week, Genus is now undergoing a so-called "Value Acceleration Programme" in ABS to improve profitability and returns from investments.

"We have taken rapid action including initiating a comprehensive programme to accelerate the value delivery from our bovine operations," said chief executive Jorgen Kokke.

"We have also completed a strategic review of R&D activities. The company is benefitting from savings achieved in the first half and will benefit further in the second half of the year and into FY25, as we optimise resource allocation to best deliver our growth objectives."

The company said there was no change to the full-year guidance given last week, assuming that current market conditions persist for the rest of the year.

"We are seeing the positive impact of our actions to accelerate value delivery which will deliver further benefit in the second half and in subsequent years," Kokke said.

More News
28 Jun 2021 19:35

TRADING UPDATES: Anglo-Eastern tips palm oil price fall; DX expands

TRADING UPDATES: Anglo-Eastern tips palm oil price fall; DX expands

Read more
22 Jun 2021 20:34

IN BRIEF: Genus trial shows gene edited pigs resistant to PRRS virus

IN BRIEF: Genus trial shows gene edited pigs resistant to PRRS virus

Read more
22 Jun 2021 07:50

Genus provides update on PRRS virus resistance programme

(Sharecast News) - Animal genetics company Genus provided an update on its porcine reproductive and respiratory syndrome virus resistance programme as part of its capital markets event on Tuesday.

Read more
31 Mar 2021 17:13

DIRECTOR DEALINGS: Sealand Capital chair invests amid licence talks

DIRECTOR DEALINGS: Sealand Capital chair invests amid licence talks

Read more
31 Mar 2021 12:17

LONDON MARKET MIDDAY: Biden spends big; Deliveroo dives on debut

LONDON MARKET MIDDAY: Biden spends big; Deliveroo dives on debut

Read more
31 Mar 2021 09:37

BROKER RATINGS: BP cut by Morgan Stanley; Jefferies raises Hikma

BROKER RATINGS: BP cut by Morgan Stanley; Jefferies raises Hikma

Read more
25 Mar 2021 16:03

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
22 Mar 2021 14:07

IN BRIEF: Genus adds molecular biology head Jason Chin to board

IN BRIEF: Genus adds molecular biology head Jason Chin to board

Read more
26 Feb 2021 16:23

DIRECTOR DEALINGS: Hochschild, Wizz Air, Clipper Logistics Execs Sell

DIRECTOR DEALINGS: Hochschild, Wizz Air, Clipper Logistics Execs Sell

Read more
25 Feb 2021 17:04

LONDON MARKET CLOSE: Stocks Edge Lower As US Bond Yields Rise

LONDON MARKET CLOSE: Stocks Edge Lower As US Bond Yields Rise

Read more
25 Feb 2021 16:15

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
25 Feb 2021 13:49

Thursday broker round-up

(Sharecast News) - Medica Group: Liberum initiates at buy with a target price of 200p.

Read more
25 Feb 2021 12:04

LONDON MARKET MIDDAY: Stocks Notch Moderate Gains Ahead Of US Data

LONDON MARKET MIDDAY: Stocks Notch Moderate Gains Ahead Of US Data

Read more
25 Feb 2021 09:42

Genus Posts "Very Strong" Interim Results Despite Covid-19 Impact

Genus Posts "Very Strong" Interim Results Despite Covid-19 Impact

Read more
25 Feb 2021 09:33

BROKER RATINGS: AstraZeneca, Reckitt And Tesco Receive Upgrades

BROKER RATINGS: AstraZeneca, Reckitt And Tesco Receive Upgrades

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.